Comparative Pharmacology
Head-to-head clinical analysis: ADALAT versus CARDENE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ADALAT versus CARDENE.
ADALAT vs CARDENE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dihydropyridine calcium channel blocker; inhibits calcium ion influx across cardiac and vascular smooth muscle cells, reducing peripheral vascular resistance and blood pressure.
Cardene (nicardipine) is a dihydropyridine calcium channel blocker that inhibits the transmembrane influx of calcium ions into vascular smooth muscle and cardiac muscle. It dilates peripheral arterioles, reducing systemic vascular resistance and blood pressure, and also has coronary vasodilatory effects.
10-20 mg orally three times daily; extended-release: 30-60 mg orally once daily; maximum 120 mg/day.
20-40 mg orally three times daily.
None Documented
None Documented
Terminal elimination half-life: 2-5 hours (immediate-release); 8-14 hours (extended-release). Context: shorter half-life necessitates multiple daily dosing for immediate-release; extended-release allows once-daily dosing.
1.5-2 hours (terminal); prolonged in hepatic impairment (up to 6-8 hours)
Renal: 70-80% as metabolites; Fecal: 15-20% as metabolites; <1% unchanged in urine
Renal: 60% as metabolites, 10% unchanged; Fecal: 35%
Category C
Category C
Calcium Channel Blocker
Calcium Channel Blocker